Naphthyridin-2(1H)-one Derivatives for Tuberculosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis therapies are lengthy, require daily dosing, and fail to effectively combat multi-drug resistant strains, necessitating the development of shorter, more potent agents that can be taken less frequently and are effective against Mycobacterium tuberculosis.
Innovation Solution
Development of a compound of Formula (I) or its pharmaceutically acceptable salt, solvate, or N-oxide, which is a naphthyridin-2(1H)-one derivative, for use in treating tuberculosis and bacterial infections, offering a high barrier to resistance and efficacy against multi-drug resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current tuberculosis therapy (combination therapy with isoniazid, rifampin, pyrazinamide and ethambutol) is used, then bacterial infection is treated, but treatment duration is lengthy (6 months) and requires daily dosing
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified pharmacological properties. The naphthyridin-2(1H)-one derivatives exhibit different potency and pharmacokinetic parameters compared to existing TB drugs, enabling shorter treatment courses while maintaining efficacy against Mycobacterium tuberculosis
Solution Approach 2:
The patent employs composite materials through the design of complex multi-component molecular structures. The compounds combine naphthyridin-2(1H)-one core structures with various substituent groups (piperidinyl, piperazinyl, morpholino rings), creating composite molecular architectures that achieve both potency and reduced treatment duration
2Reliability
If current tuberculosis therapy is used, then bacterial infection is treated, but compliance is poor due to daily dosing requirement
Solution Approach 1:
The patent changes dosing frequency parameters by developing compounds with extended half-lives and sustained release properties. The novel naphthyridin-2(1H)-one derivatives are designed to maintain therapeutic levels over longer periods, enabling less frequent administration such as once-weekly or once-monthly dosing regimens
Solution Approach 2:
The patent implements periodic action through extended-dosing regimens. Instead of continuous daily dosing, the therapy employs periodic administration intervals (weekly, bi-weekly, or monthly doses), reducing patient burden while maintaining therapeutic effectiveness through the prolonged activity of the novel compounds
3Reliability
If current tuberculosis therapy is used, then bacterial infection is treated, but multi-drug resistant strains emerge
Solution Approach 1:
The patent applies segmentation by developing combination therapies that use multiple novel compounds with different mechanisms of action simultaneously. This multi-target approach segments the resistance problem, making it harder for bacteria to develop resistance to all components at once, thereby raising the barrier to resistance
Solution Approach 2:
The patent inverts the traditional approach by focusing on developing entirely new chemical entities with novel mechanisms of action rather than optimizing existing drugs. The naphthyridin-2(1H)-one derivatives represent a paradigm shift, targeting bacterial pathways differently from conventional TB medications, thus creating a higher barrier to resistance
Data Source
AI summary
Compounds of Formula (I) wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.